Literature DB >> 12928915

Association study between Alzheimer's disease and genes involved in Abeta biosynthesis, aggregation and degradation: suggestive results with BACE1.

Jordi Clarimón1, Jaume Bertranpetit, Francesc Calafell, Mercè Boada, Lluís Tàrraga, David Comas.   

Abstract

BACKGROUND: Amyloid beta-peptide (Abeta) biosynthesis, aggregation and degradation constitute three important steps to consider in the study of pathological mechanisms involved in Alzheimer's disease (AD). Several proteins have been suggested as involved in each of these processes: proteolytic cleavage of the amyloid precursor protein by the beta-site APP cleaving enzyme (BACE), increased amyloid fibril formation by the activity of the acetylcholinesterase (ACHE gene), and degradation of Abeta aggregates by the plasmin system have been exhaustively documented.
METHODS: A case-control design was used to evaluate the possible association between candidate genes involved in these three processes and AD. We analysed three polymorphisms located at the BACE1 gene, one polymorphism at the ACHE gene, and two variants located at the tissue plasminogen activator and plasminogen activator inhibitor-1 (genes TPA and PAI- 1, respectively), both part of the plasmin system.
RESULTS: We found an association between BACE1 exon 5 GG genotype and AD (age-and gender-adjusted odds ratio = 2.14, P =0.014). Although a similar association was reported previously by Nowotny and collaborators only in subjects carrying the epsilon4-allele of the apolipoprotein E gene (APOE), we did not detect this effect. However,when we combined our results with those previously reported, a clear increase of the risk to develop AD appeared in subjects carrying both the BACE1 exon 5 GG genotype and the APOE epsilon4-allele (crude OR = 2.2, P = 0.004).
CONCLUSION: These data suggest a possible genetic relation between BACE1 and AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928915     DOI: 10.1007/s00415-003-1127-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease.

Authors:  Weihui Zhou; Fang Cai; Yu Li; George S Yang; Kathleen D O'Connor; Robert A Holt; Weihong Song
Journal:  J Mol Neurosci       Date:  2010-05-09       Impact factor: 3.444

2.  Characterization of the human beta-secretase 2 (BACE2) 5'-flanking region: identification of a 268-bp region as the basal BACE2 promoter.

Authors:  Bryan Maloney; Yuan-Wen Ge; Nigel H Greig; Debomoy K Lahiri
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

3.  Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation.

Authors:  Manel G Medina; Maria Dolores Ledesma; Jorge E Domínguez; Miguel Medina; Delia Zafra; Francesc Alameda; Carlos G Dotti; Pilar Navarro
Journal:  EMBO J       Date:  2005-04-21       Impact factor: 11.598

4.  New Alzheimer's disease locus on chromosome 8.

Authors:  V Giedraitis; M Hedlund; L Skoglund; E Blom; S Ingvast; R Brundin; L Lannfelt; A Glaser
Journal:  J Med Genet       Date:  2006-07-06       Impact factor: 6.318

5.  BACE1 polymorphisms do not influence platelet membrane beta-secretase activity or genetic susceptibility for Alzheimer's disease in the Northern Irish population.

Authors:  S Todd; A J McKnight; W W Liu; R Carson; S Heggarty; B McGuinness; G B Irvine; D Craig; A P Passmore; J A Johnston
Journal:  Neuromolecular Med       Date:  2008-06-26       Impact factor: 3.843

6.  BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease.

Authors:  Annica Sjölander; Henrik Zetterberg; Ulf Andreasson; Lennart Minthon; Kaj Blennow
Journal:  Mol Neurodegener       Date:  2010-09-17       Impact factor: 14.195

7.  Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice.

Authors:  Matthew J Chiocco; Laura Shapiro Kulnane; Linda Younkin; Steve Younkin; Geneviève Evin; Bruce T Lamb
Journal:  J Biol Chem       Date:  2004-09-27       Impact factor: 5.157

8.  Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.

Authors:  Philip T T Ly; Yili Wu; Haiyan Zou; Ruitao Wang; Weihui Zhou; Ayae Kinoshita; Mingming Zhang; Yi Yang; Fang Cai; James Woodgett; Weihong Song
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

9.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

10.  The synergy factor: a statistic to measure interactions in complex diseases.

Authors:  Mario Cortina-Borja; A David Smith; Onofre Combarros; Donald J Lehmann
Journal:  BMC Res Notes       Date:  2009-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.